Europe Vaccine Contract Manufacturing Market Size & Outlook

The vaccine contract manufacturing market in Europe is expected to reach a projected revenue of US$ 1,944.5 million by 2030. A compound annual growth rate of 5.3% is expected of Europe vaccine contract manufacturing market from 2025 to 2030.
Revenue, 2024 (US$M)
$1,426.2
Forecast, 2030 (US$M)
$1,944.5
CAGR, 2025 - 2030
5.3%
Report Coverage
Europe

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe vaccine contract manufacturing market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Europe vaccine contract manufacturing market highlights

  • The Europe vaccine contract manufacturing market generated a revenue of USD 1,426.2 million in 2024.
  • The market is expected to grow at a CAGR of 5.3% from 2025 to 2030.
  • In terms of segment, attenuated vaccine was the largest revenue generating vaccine type in 2024.
  • DNA Vaccines is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
  • Country-wise, France is expected to register the highest CAGR from 2025 to 2030.


Europe data book summary

Market revenue in 2024USD 1,426.2 million
Market revenue in 2030USD 1,944.5 million
Growth rate5.3% (CAGR from 2025 to 2030)
Largest segmentAttenuated vaccine
Fastest growing segmentDNA Vaccines
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSubunit Vaccines, Attenuated Vaccine, Inactivated Vaccine, Toxoid Vaccines, DNA Vaccines
Key market players worldwideLonza Group Ltd, FUJIFILM Holdings Corp, Merck KGaA, Catalent Inc, Icon PLC, Syngene, Curia, Ajinomoto Co Inc, IDT Biologika


Other key industry trends

  • In terms of revenue, Europe region accounted for 30.9% of the global vaccine contract manufacturing market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 1,981.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Vaccine Contract Manufacturing Market Companies

Name Profile # Employees HQ Website
IDT Biologika View profile 1001-5000 Dessau, Sachsen-Anhalt, Germany, Europe https://idt-biologika.de/
Syngene View profile 1001-5000 Bangalore, Karnataka, India, Asia http://www.syngeneintl.com
Curia View profile 1001-5000 Albany, New York, United States, North America https://curiaglobal.com
Ajinomoto Co Inc View profile 43318 15-1, Kyobashi 1-chome, Chuo-ku, Tokyo, Japan, 104-8315 http://www.ajinomoto.co.jp
Catalent Inc View profile 17219 14 Schoolhouse Road, Somerset, NJ, United States, 08873 https://www.catalent.com
Icon PLC View profile 41150 South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 https://www.iconplc.com
FUJIFILM Holdings Corp View profile 83784 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 http://www.fujifilmholdings.com
Lonza Group Ltd View profile 18000 Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 https://www.lonza.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com

Europe vaccine contract manufacturing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.


Attenuated vaccine was the largest segment with a revenue share of 29.93% in 2024. Horizon Databook has segmented the Europe vaccine contract manufacturing market based on subunit vaccines, attenuated vaccine, inactivated vaccine, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.


Europe was the second-largest contributor to the vaccine contract manufacturing market with a 31.0% share in 2023. Furthermore, government bodies and funding agencies have played a pivotal role in funding vaccine research.

Moreover, presence of the European Investment Bank (EIB) financing facilities which are engaged in supporting R&D of vaccines for combating infectious diseases through various initiatives is expected to drive the country market.

For example, InnovFin Infectious Diseases initiative by the EIB aimed at stimulating investments for the development of innovative vaccines. These factors are contributing to the segment growth over the forecast period.

Reasons to subscribe to Europe vaccine contract manufacturing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe vaccine contract manufacturing market databook

  • Our clientele includes a mix of vaccine contract manufacturing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe vaccine contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Europe vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe vaccine contract manufacturing market size, by country, 2018-2030 (US$M)

Europe Vaccine Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)

Europe vaccine contract manufacturing market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online